Trials / Recruiting
RecruitingNCT04731844
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Detailed description
The purpose of this study is to determine whether the supplement of curcumin plus peperine can prevent or delay the progression of prostate cancer, monoclonal gammopathy of unknown significant, or low-risk smoldering myeloma into a more aggressive cancer which requires treatment. The investigator will be evaluating a marker in patients blood called MIC-1 to determine whether it could be a useful predictor of whether the disease is improving or progressing.
Conditions
- Prostate Cancer
- Multiple Myeloma
- Smoldering Multiple Myeloma (SMM)
- Monoclonal Gammopathy of Undetermined Significance
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Curcumin plus Piperine | Curcumin with piperine is a well-tolerated over-the-counter supplement. |
Timeline
- Start date
- 2021-12-14
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
- First posted
- 2021-02-01
- Last updated
- 2024-07-12
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04731844. Inclusion in this directory is not an endorsement.